| |Compound Summary for:
Also known as: Cymbalta, Yentreve, (S)-Duloxetine, 116539-59-4, Xeristar, Duloxetine [INN:BAN], CHEBI:36795, duloxetine, (+)-isomer
NOS Molecular Weight:
Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.
Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia.
Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake. From: DrugBank
| |Show subcontent titlesTable of Contents
| || |
Use and Manufacturing
Biomedical Effects and Toxicity
Safety and Handling
Environmental Fate and Exposure Potential
Exposure Standards and Regulations
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties